Doxy-PEP reduces chlamydia and syphilis by around ninety per cent in trials but gonorrhoea by roughly half or less. The explanation is not that gonorrhoea is somehow harder to reach; it is that a large proportion of circulating strains are already resistant to tetracyclines, so the drug arrives and does nothing.
How did that resistance develop?
Tetracyclines were used to treat gonorrhoea decades ago and were abandoned as resistance spread. Neisseria gonorrhoeae acquires resistance genes readily, both by mutation and by taking up genetic material from other bacteria, including the harmless Neisseria species that live in the throat. Tetracycline resistance became widespread and has persisted even though the drugs are no longer used for treatment, because there is no strong pressure to lose it.
Does the effect vary by place?
Yes, and this is why doxy-PEP results differ between settings. Where a higher proportion of local strains carry tetracycline resistance, the observed effect on gonorrhoea is smaller. This matters for the UK, where gonorrhoea is the most commonly diagnosed of the bacterial infections in men who have sex with men, and it is one reason UK implementation has been more cautious than in some other countries.
Why is the throat particularly difficult?
Pharyngeal gonorrhoea is the hardest site to prevent and the hardest to treat. Antibiotic concentrations in throat tissue are lower than elsewhere, and the throat is where gonorrhoea acquires resistance genes from neighbouring organisms. Trial effects on throat gonorrhoea were the weakest of any site, and throat infections are almost always silent, so they are found by swabbing rather than by symptoms.
Could doxy-PEP make gonorrhoea resistance worse?
It is the central concern. Repeated exposure to a drug that many strains already resist applies selection pressure without much preventive benefit, which is the least favourable combination. Surveillance is ongoing, and it is a substantial part of why provision is targeted at people with repeated infections rather than offered generally.
What actually reduces gonorrhoea risk?
Three things, none of them doxycycline. The meningococcal B vaccine offers partial protection, estimated at around a third, and England has introduced a targeted programme through sexual health services. Condoms reduce transmission substantially, including for oral sex where a barrier is used. And three-monthly screening at all three sites finds and treats infections before they circulate further, which is prevention at population level even though it is detection at individual level.
Should that change whether you use doxy-PEP?
It depends on which infections you actually keep getting. If your history is repeated syphilis or chlamydia, doxy-PEP addresses that well and is worth having. If it is repeated gonorrhoea and nothing else, the benefit is smaller and the vaccine plus regular screening may be the better use of a clinic appointment. Bring your actual history to the conversation rather than a general sense that you get infections a lot.
What about treatment if you get it anyway?
Gonorrhoea is treated with an intramuscular ceftriaxone injection in the UK, and a test of cure is recommended two weeks later, particularly for throat infections. Attend that follow-up even if you feel fine, because it is how resistant strains are identified.
The honest summary
Doxy-PEP is a syphilis and chlamydia intervention that happens to have a modest side effect on gonorrhoea. Expecting it to solve repeated gonorrhoea will lead to disappointment.
Could a different antibiotic work better?
In principle, but the options are poor. The drugs gonorrhoea remains reliably susceptible to are the ones being preserved for treatment, and using them prophylactically would accelerate the loss of the last effective treatments. This is why nobody is proposing ceftriaxone prophylaxis, and it is a reasonable position rather than a lack of imagination.
What does the future look like?
Vaccination is the more promising direction, since it reduces infections without antibiotic pressure. The meningococcal B vaccine is a repurposed stopgap, and purpose-built gonorrhoea vaccines are in development. Until then, screening and prompt treatment do most of the work.